000 02323nam  2200373za 4500
0019.874408
003CaOODSP
00520221107164202
006m    go  d f      
007cr |||||||||||
008190606e199810##onc ||| ob   f000 0 eng d
040 |aCaOODSP|beng
043 |an-cn---
0861 |aYM32-6/98-1E-PDF
1001 |aForge, Frédéric, |eauthor.
24510|aRecombinant bovine somatotropin (rbST) / |cprepared by Frédéric Forge, Science and Technology Division.
264 0|a[Ottawa] : |bParliamentary Research Branch, |cOctober 1998.
300 |a1 online resource (18 unnumbered pages).
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
4901 |a[Modular backgrounders]|vPRB 98-1E
500 |aCaption title.
500 |aIssued also in French under title: La somatotropine bovine recombinante (STbr).
504 |aIncludes bibliographical references.
5050 |aWhat's new? -- Introduction -- What is rbST? -- The impact of rbST on health -- The impact of rbST on the dairy industry -- The regulation of rbST in Canada -- Situaation with respect of rbST in Canada -- rbST in other countries -- What should be the decision on rbST?
520 |a"Recombinant bovine somatotropin (rbST) is a veterinary medication produced by genetic engineering. When administered to lactating cows, it can increase their milk production by between 10 and 15%. Approval of this product has been subject to controversy in this country since the early 1990s, primarily because of its possible effects on human health. … This document presents various issues relating to rbST and considers its effects on health and the dairy industry, its regulation in Canada, and its use abroad"--Introduction.
69207|2gccst|aHealth impact
69207|2gccst|aVeterinary medicine
7101 |aCanada.|bLibrary of Parliament. |bParliamentary Research Branch.
77508|tLa somatotropine bovine recombinante (STbr) / |w(CaOODSP)9.874412
794 |tRecombinant bovine somatotropin (rbST) / |w(CaOODSP)9.561313
830#0|a[Modular backgrounders]|vPRB 98-1E|w(CaOODSP)9.504922
85640|ahttp://publications.gc.ca|qPDF|s151 KB|uhttps://publications.gc.ca/collections/collection_2019/bdp-lop/bp/YM32-6-98-1-eng.pdf|yPRB 98-1E